• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by DermTech Inc. (Amendment)

    11/8/22 4:56:25 PM ET
    $DMTK
    Medical Specialities
    Health Care
    Get the next $DMTK alert in real time by email
    SC 13D/A 1 p22-2457sc13da.htm DERMTECH, INC.
    SECURITIES AND EXCHANGE COMMISSION  
       
    Washington, D.C. 20549  
    _______________  
       
    SCHEDULE 13D/A
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    RULE 13d-2(a)
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)
     

    DermTech, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    24984K105

    (CUSIP Number)
     

    Eleazer Klein, Esq.

    Adriana Schwartz, Esq.

    919 Third Avenue
    New York, New York 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    November 4, 2022

    (Date of Event which Requires
    Filing of this Schedule)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. [ ]

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    (Continued on following pages)

    (Page 1 of 6 Pages)

    --------------------------

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 24984K105SCHEDULE 13D/APage 2 of 6 Pages

     

    1

    NAME OF REPORTING PERSON

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    3,018,666*

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    3,018,666*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    3,018,666*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (see Item 5)

    9.99%*

    14

    TYPE OF REPORTING PERSON

    PN, IA, OO

             

     

     

    CUSIP No. 24984K105SCHEDULE 13D/APage 3 of 6 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Roderick Wong

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    3,018,666*

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    3,018,666*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    3,018,666*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (see Item 5)

    9.99%*

    14

    TYPE OF REPORTING PERSON

    HC, IN

             

     * The above-referenced shares (the “Shares”) of DermTech, Inc. (the “Issuer”) reported herein are held in the form of common stock (the “Common Stock”). The Shares are held by certain investment funds (together the “RTW Funds”), managed by RTW Investments, LP (“RTW Investments” or the “Adviser”). The Adviser, in its capacity as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of all such Shares held by the RTW Funds. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially own an aggregate of 3,018,666 Shares, or 9.99% of the Issuer’s 30,214,705 Shares deemed issued and outstanding as of October 28, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2022. Roderick Wong, M.D. (“Dr. Wong”), is the Managing Partner and Chief Investment Officer of the Adviser. This report shall not be deemed an admission that the Adviser, the RTW Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    CUSIP No. 24984K105SCHEDULE 13D/APage 4 of 6 Pages

     

    This Amendment No. 3 relates to and amends the Statement of Beneficial Ownership on Schedule 13D of the Reporting Persons, initially filed jointly by the Reporting Persons with the SEC on September 9, 2019, and amended on March 9, 2020 and January 19, 2021 (as amended, the “Schedule 13D”), with respect to the Shares of the Issuer.

    Items 5 (a)-(c) of the Schedule 13D are hereby amended to the extent hereinafter expressly set forth. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Schedule 13D.

     

    Item 5. INTEREST IN SECURITIES OF THE COMPANY.
       
    Items 5 (a)-(c) of the Schedule 13D are hereby amended and restated as follows:

     

    (a) The aggregate percentage of Shares reported to be beneficially owned by the Reporting Persons is based upon 30,214,705 Shares outstanding as of October 28, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed by with the SEC on November 3, 2022.

    (b) See rows (7) through (10) of the cover page to this Schedule 13D for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

    (c) The transactions in the Shares effected by the Reporting Persons during the past sixty (60) days, which were all in the open market, are set forth on Schedule 1 attached hereto.

     

     

     

    CUSIP No. 24984K105SCHEDULE 13D/APage 5 of 6 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    DATED: November 8, 2022

     

    RTW INVESTMENTS, LP  
       
       
    By: /s/ Roderick Wong, M.D.  
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
       
       
       
    /s/ Roderick Wong, M.D.  
    RODERICK WONG, M.D.  
           

     

     

     

     

    CUSIP No. 24984K105SCHEDULE 13D/APage 6 of 6 Pages

     

    SCHEDULE 1

     

    Transactions in the Shares of the Issuer by the Reporting Persons During the Past Sixty (60) Days

     

    The following table sets forth all transactions in the Shares effected during the past sixty (60) days by the Reporting Persons. Except as noted below, all such transactions were effected in the open market through brokers and the price per share includes commissions.

     

     

    Trade Date Shares Purchased (Sold) Price Per Share ($)
    11/04/2022 (100,000) 1.7666
         

     

     

    Get the next $DMTK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DMTK

    DatePrice TargetRatingAnalyst
    7/18/2022$48.00Outperform
    Oppenheimer
    6/14/2022$38.00 → $19.00Buy
    BTIG Research
    1/7/2022$26.00Overweight
    Stephens
    1/7/2022Overweight
    Stephens & Co.
    10/15/2021$50.00Outperform
    Cowen
    More analyst ratings

    $DMTK
    SEC Filings

    See more
    • DermTech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - DermTech, Inc. (0001651944) (Filer)

      6/20/24 4:03:19 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - DermTech, Inc. (0001651944) (Filer)

      6/18/24 8:10:13 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Other Events

      8-K - DermTech, Inc. (0001651944) (Filer)

      5/17/24 4:05:27 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Sun Kevin M covered exercise/tax liability with 445 shares, decreasing direct ownership by 0.17% to 269,216 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/12/24 8:07:07 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • Akhavan Ramin covered exercise/tax liability with 3,745 shares, decreasing direct ownership by 3% to 128,425 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/7/24 8:06:44 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • Sun Kevin M covered exercise/tax liability with 4,945 shares, decreasing direct ownership by 2% to 269,661 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/7/24 8:04:16 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer resumed coverage on DermTech with a new price target

      Oppenheimer resumed coverage of DermTech with a rating of Outperform and set a new price target of $48.00

      7/18/22 9:13:48 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • BTIG Research reiterated coverage on DermTech with a new price target

      BTIG Research reiterated coverage of DermTech with a rating of Buy and set a new price target of $19.00 from $38.00 previously

      6/14/22 8:37:49 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • Stephens initiated coverage on DermTech with a new price target

      Stephens initiated coverage of DermTech with a rating of Overweight and set a new price target of $26.00

      1/7/22 7:32:05 AM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DermTech Files for Voluntary Chapter 11 Protection

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DMT), while simultaneously conducting a process to sell substantially all of its assets. Through the bankruptcy process, the Company intends to safeguard the interest of stakeholders and maximize the value of its assets. DermTech

      6/18/24 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Reports First-Quarter 2024 Financial Results

      - Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year - Test revenue increased 7 percent versus the first quarter of 2023 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. Total revenue was $3.8 million, an 11 percent increase from

      5/14/24 4:05:00 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in

      4/18/24 4:15:00 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by DermTech Inc.

      SC 13G - DermTech, Inc. (0001651944) (Subject)

      4/26/24 6:19:55 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by DermTech Inc. (Amendment)

      SC 13G/A - DermTech, Inc. (0001651944) (Subject)

      2/8/24 5:18:40 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by DermTech Inc. (Amendment)

      SC 13D/A - DermTech, Inc. (0001651944) (Subject)

      12/12/23 4:19:36 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Financials

    Live finance-specific insights

    See more
    • DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in

      4/18/24 4:15:00 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Reports Fourth-Quarter 2023 Financial Results

      - Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 55 percent year-over-year - Test revenue increased 38 percent versus the fourth quarter of 2022 - Estimated cash runway into the first quarter of 2025 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results. "We reported sustained improvement in many of our key performance indicators during the second half of last year and will continue emphasizing average selling price (ASP) and revenue growth in 2024," said Bret Christensen, CEO, DermTech. "We've aligned our commer

      2/29/24 4:01:00 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Announces Release Date for Fourth-quarter 2023 Financial Results

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, DermTech will issue its fourth-quarter 2023 earnings press release. For participants interested in asking questions during the teleconference, please register using the following link. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during

      2/13/24 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Leadership Updates

    Live Leadership Updates

    See more
    • DermTech, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 15, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for

      11/7/23 4:13:58 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 15, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options

      10/18/23 3:55:34 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Appoints Mark Aguillard as Chief Commercial Officer

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech's overall commercial strategy and execution. Commenting on Mr. Aguillard's appointment, Bret Christensen, DermTech's CEO said, "I'd like to welcome Mark to the team. We are confident that his demonstrated success and wide breadth of commercial and payer access experience will serve us well during this transformational period as we focus on generating reimbursed tests to grow revenue. Mark's leadership will be i

      9/11/23 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care